HONG KONG, Nov. 11, 2019 /PRNewswire/ -- Global Cord Blood
Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood
collection, laboratory testing, hematopoietic stem cell processing
and stem cell storage services, today announced the
appointment of a new independent non-executive director to the
Board of Directors of the Company (the "Board").
In order to further strengthen GCBC's Board composition and the
Company's leadership position in China's evolving cord blood banking industry,
the Board is delighted to announce that Mr. Jack Chow will join the Board as a class B
independent non-executive director, effective immediately. Mr.
Jack Chow will replace Mr.
Mark Chen as a member of the
Company's Audit Committee and Ms. Jennifer
Weng as a member of the Company's Special Committee; he will
also join the Board's Compensation and Nominating and Corporate
Governance Committees.
Mr. Chow currently serves as a partner of the VMS Group and is
responsible for the strategic direction and development of VMS
Private Equity. Prior to joining VMS Group, Mr. Chow was an audit
partner at KPMG with extensive experience in raising funds for
clients in Hong Kong and overseas
stock exchanges, and advising clients on group restructuring and
M&A arrangements. Mr. Chow is a former member of the Listing
Committee of the HKEX. He was also the Chairman of Mainland
Development Strategies Advisory Panel of the Hong Kong Institute of
Certified Public Accountants and Council Member of Hong Kong
Institute of Chartered Secretaries.
"We are very delighted and excited to welcome Mr. Chow to join
the team," said Ms. Ting Zheng, Chairperson and Chief
Executive Officer of GCBC. "We believe that with his extensive
professional experience and broad network in the finance and
investment industry, Mr. Chow will be an invaluable addition to the
Board and bring new perspectives and additional resources to
advance the Company in the future."
About Global Cord Blood Corporation
Global Cord Blood Corporation is the first and largest umbilical
cord blood banking operator in China in terms of geographical coverage and
the only cord blood banking operator with multiple
licenses. Under current PRC government regulations, only one
licensed cord blood banking operator is permitted to operate in
each licensed region and no new licenses will be granted before
2020 in addition to the seven licenses authorized as of
today. Global Cord Blood Corporation provides cord blood
collection, laboratory testing, hematopoietic stem cell processing,
and stem cell storage services. For more information, please visit
our website at http://www.globalcordbloodcorp.com.
View original
content:http://www.prnewswire.com/news-releases/global-cord-blood-corporation-appoints-mr-jack-chow-as-an-independent-non-executive-director-300955246.html
SOURCE Global Cord Blood Corporation